Treatment of adolescent girls with polycystic ovary syndrome and insulin resistance

Abstract

Aim. Polycystic ovary syndrome is a common cause of infertility. In addition, polycystic ovary syndrome is often associated with metabolic complications. In most women hyperandrogenic manifestations occur during puberty. Early detection of polycystic ovary syndrome and associated metabolic problems can solve the problem of puberty and prevent infertility, metabolic syndrome, and diabetes mellitus type 2 in women of reproductive age. One of the objectives of the study was to evaluate the effectiveness of the simultaneous use of a combined oral preparation (ethinyl estradiol + drospirenone) and metformin in adolescent girls with polycystic ovary syndrome.Materials and methods. 113 adolescent girls with hyperandrogenism from 14 to 19 years were included. 32 of these girls aged 14–18 years with polycystic ovary syndrome were treated with medication ethinyl estradiol + drospirenone. Of these 32 patients, 20 girls with insulin resistance were obtained simultaneously with metformin. The following methods were used: examination, evaluation of hair (Ferriman-Gallwey score), pelviс ultrasound, determination of hormone status (LH, FSH, PRL, 17-OHP, E2 , TSH, DHEA-s, SHBG, T), glucose, insulin, and glucose tolerance test. The diagnostic technique used the Sultan C. criteria of polycystic ovary syndrome (2004).Results.A reduction in the frequency characteristics after treatment was shown: of laboratory hyperandrogenism 90.6% , dermopathy 65.6% , insulin resistance 43.8%, hyperinsulinemia 18.8%, ultrasonic signs of PCOS 34.4%.Conclusions. The study results confirm the efficacy of the treatment of polycystic ovary syndrome with insulin resistance during puberty by Low-dose combined oral preparation (0.03 mg ethinyl estradiol and 3 mg drospirenone) in combination with metformin.

Keywords

• девушки-подростки
• синдром поликистозных яичников
• инсулинорезистентность
• гиперандрогения
• дроспиренон
• метформин